Massachusetts-based SQZ Biotechnologies, a cell therapy company, has raised $72 million in Series C financing. The investors included Everblue, Illumina Ventures, Invus, Orient Life, Viva Ventures Biotech Group, Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension and Polaris.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: